Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin for drug relapse prevention
2023-504518-31-01Phase 2Authorised
- Sponsor
- Fondazione Santa Lucia IRCCS
- Start
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in substance use disorder (SUD) comparing Oxytocin (Syntocinon) nasal spray with Placebo nasal spray (2 arms). Primary endpoint: Cue-incubation of craving and neural activation. Planned start May 2026; status: authorised.
02
Drugs
oxytocin
03
Conditions
substance use disorder (SUD)
Beyond the preview
Go deeper on 2023-504518-31-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504518-31-01.